Adherence to oral endocrine therapy by menopausal status: post hoc insights from a remote monitoring randomized trial
Oral adjuvant endocrine therapy (AET) improves survival in hormone receptor-positive breast cancer, but younger, premenopausal women often struggle with adherence. In a post hoc analysis of a randomized trial (N = 304), app-based remote symptom monitoring improved 12-month AET adherence among premenopausal women (App-only: 53.9% vs. EUC: 25.0%), with no benefit for postmenopausal women. Findings suggest remote monitoring may help close adherence gaps in younger patients. Prospectively registered on ClinicalTrials.gov: NCT03592771.
Authors
- Teresa M. Waters (ORCID: https://orcid.org/0000-0002-3823-5177)
- Janeane N. Anderson (ORCID: https://orcid.org/0000-0003-2602-6957)
- Gregory A. Vidal (ORCID: https://orcid.org/0000-0003-3325-6224)
- Rebecca A. Krukowski (ORCID: https://orcid.org/0000-0001-9193-2783)
- Xin Hu (ORCID: https://orcid.org/0009-0001-9117-8300)
- Edward Stepanski (ORCID: https://orcid.org/0000-0003-3167-2347)
- Ilana Graetz
- Lee S. Schwartzberg
Institutions
- University of Nevada, Reno (US)
- Emory University (US)
- University of Tennessee Health Science Center (US)
- Augusta University (US)
- Renown Health (US)
- West Cancer Center (US)
- Ovation Fertility (US)
- University of Virginia (US)
Publication Details
- Journal
- npj Breast Cancer
- Published
- 2026-01-28
- DOI
- https://doi.org/10.1038/s41523-026-00900-9
- Primary Topic
- Medication Adherence and Compliance
- Type
- article
- Field-Weighted Citation Impact
- 0.00